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A disintegrin and metalloproteinases (ADAMs) 
are zinc-dependent proteinases related to matrix 
metalloproteinases (MMPs). The combination 
of metalloproteinase and disintegrin domains 
is characteristic of all ADAMs. Although 38 
ADAMs have been identified, ADAM10 has 
emerged as one of several members that regu-
lates cell processes by cleaving or shedding 
extracellular domains of numerous transmem-
brane receptors and ligands. ADAMs can also 
activate  vital  signaling  pathways  that  require 
regulated intramembrane proteolysis of recep-
tor–ligand complexes. Studies in Drosophila and 
in vitro experiments using ADAM10-deficient 
mouse embryonic fibroblasts (MEFs) and pro-
tease inhibitors have generated a growing list of 
putative ADAM10 substrates, including the 
ErbB2 receptor, several ErbB ligands, Notch 
receptors, Delta-like 1 (Dll1), ephrins, FasL, the 
IL-6 receptor, CXCL-16, and CD23 (Blobel, 
2005; Crawford et al., 2009). However, in utero 
lethality of ADAM10/ mice has hindered 
examination of these cleavage events in vivo 
(Hartmann et al., 2002).
ADAM-mediated cleavage of Notch recep-
tors  initiates  an  irreversible  signaling  cascade 
that dictates cell-fate processes (Kopan and Ilagan, 
2009). Recently, many studies have described the 
importance of Notch signaling in lymphocyte 
development (Tanigaki and Honjo, 2007). How-
ever, as described by Kopan and Ilagan (2009), 
the  identity  of  the  proteinase  that  initiates 
Notch signaling in mammalian cells is the sub-
ject of great controversy. Initially, two indepen-
dent groups using in vitro models concluded that 
ADAM17 (TNF-converting enzyme) initiates 
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The proteolytic activity of a disintegrin and metalloproteinase 10 (ADAM10) regulates  
cell-fate decisions in Drosophila and mouse embryos. However, in utero lethality of ADAM10/ 
mice has prevented examination of ADAM10 cleavage events in lymphocytes. To investigate 
their role in B cell development, we generated B cell–specific ADAM10 knockout mice. 
Intriguingly, deletion of ADAM10 prevented development of the entire marginal zone B cell 
(MZB) lineage. Additionally, cleavage of the low affinity IgE receptor, CD23, was profoundly 
impaired, but subsequent experiments demonstrated that ADAM10 regulates CD23 cleavage 
and MZB development by independent mechanisms. Development of MZBs is dependent on 
Notch2 signaling, which requires proteolysis of the Notch2 receptor by a previously uniden-
tified proteinase. Further experiments revealed that Notch2 signaling is severely impaired  
in ADAM10-null B cells. Thus, ADAM10 critically regulates MZB development by initiating 
Notch2 signaling. This study identifies ADAM10 as the in vivo CD23 sheddase and an impor-
tant regulator of B cell development. Moreover, it has important implications for the treat-
ment of numerous CD23- and Notch-mediated pathologies, ranging from allergy to cancer.
© 2010 Gibb et al.  This article is distributed under the terms of an Attribution–
  Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.jem.org/misc/terms.shtml). After six months   
it is available under a Creative Commons License (Attribution–Noncommercial–
Share Alike 3.0 Unported license, as described at http://creativecommons.org/ 
licenses/by-nc-sa/3.0/).
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intracellular domain (NICD) that translocates to the nucleus 
and binds the transcription factor RBP-J. This activated 
complex  drives  the  expression  of  Notch2  target  genes,   
including complement receptors (CD21/35), deltex-1 (Dtx1), 
hairy enhancer of split 1 (Hes1), and Hes5 (Saito et al., 2003; 
Tanigaki and Honjo, 2007). Deletion of Dll1 from nonhe-
matopoietic cells (Hozumi et al., 2004), or Notch2 or RBP-J 
from B cells profoundly inhibits MZB development (Tanigaki 
et al., 2002; Saito et al., 2003). Many other regulators of 
Notch2 signaling have been identified. However, the metal-
loproteinase necessary for initiating signaling is unknown, 
and a role for ADAM10 in B cell development or Notch2 
signaling has not been examined.
To date, the only putative ADAM10 substrates expressed 
by B cells are the low affinity IgE receptor, CD23 (Weskamp 
et al., 2006; Lemieux et al., 2007), and FasL (Schulte et al., 
2007). CD23, expressed on mouse B cells and follicular DCs 
(FDCs), is a known regulator of allergic and inflammatory re-
sponses. Catabolic shedding of CD23 from the cell surface is an 
important processing event that regulates its function (Conrad 
et al., 2007; Gould and Sutton, 2008). CD23 cleavage may also 
regulate the development of MZBs. Precursors of MZBs, in-
cluding transitional type 2 (T2) B cells and pre-MZBs (PMZBs), 
down-regulate surface expression of CD23 as they differentiate 
into MZBs (Pillai et al., 2005). However, the role of CD23 
cleavage in B cell development has not been examined.
Two independent groups have demonstrated the ability 
of ADAM10 to cleave CD23 in vitro (Weskamp et al., 2006; 
Lemieux  et  al.,  2007).  These  studies  generated  intriguing 
questions  about  the  role  of  ADAM10  in  the  regulation   
of CD23-mediated immune responses. However, earlier in   
vitro experiments demonstrated the ability of ADAM8 and 
ADAM15 to cleave CD23 (Fourie et al., 2003). In addition, 
a recent study determined that MMP-9 is the principal shed-
dase of CD23 in LPS-treated mice (Jackson et al., 2009). 
Given that many ADAM substrates, including Notch1 and 
CD23, can be cleaved by multiple proteases in vitro, the 
physiological relevance of ADAM10-mediated cleavage in   
B cells is unclear. This requires examination of ADAM10-
null B cells from B cell–specific knockout mice.
Given the importance of ADAM10 in embryonic devel-
opment and its potential role in thymocyte development, we 
formally tested the hypothesis that ADAM10 regulates B cell 
development. Generation of B cell–specific knockout mice 
revealed that ADAM10 is a critical regulator of Notch2   
signaling, and as a result, it is essential for the development   
of  the  entire  MZB  lineage.  Additionally,  we  report  that 
ADAM10 is the primary sheddase of CD23 in vivo. More-
over, despite reports of compensatory roles for ADAMs in 
vitro and in thymocytes, other proteases did not compensate 
for the lack of ADAM10 activity in B cells.
RESULTS
Generation of B cell–specific ADAM10 knockout mice
To  determine  the  role  of  ADAM10  in  B  cell  develop-
ment, we generated B cell–specific ADAM10 knockouts 
Notch1 signaling by cleaving Notch1 in monocytic pre-
cursors and MEFs (Brou et al., 2000; Mumm et al., 2000). 
Thus, ADAM17 is often referenced in the literature as the 
relevant proteinase that initiates Notch signaling in lympho-
cytes (Radtke et al., 2004). However, generation of ADAM17 
mutant and conditional knockout mice has not resulted in 
Notch-related phenotypes in lymphocytes (Li et al., 2007; Le 
Gall  et  al.,  2009).  In  contrast,  ADAM10-deficient  mouse 
embryos display many features also observed in nonviable 
Notch1/ embryos (Swiatek et al., 1994; Hartmann et al., 
2002).  To  further  complicate  this  issue,  multiple  in  vitro 
studies have demonstrated that ADAM17 cleaves numerous 
ADAM10 substrates (Hinkle et al., 2004; Sahin et al., 2004), 
whereas  ADAM10  can  cleave  many  ADAM17  substrates 
from  ADAM17/  MEFs  (Le  Gall  et  al.,  2009).  Most   
recently, two groups using ADAM10/ MEFs concluded 
that ADAM10 mediates ligand-dependent Notch1 cleavage, 
whereas other proteases regulate ligand-independent cleav-
age (Bozkulak and Weinmaster, 2009; van Tetering et al., 
2009). Finally, Tian et al. (2008) reported that ADAM10 
conditional knockout thymocytes have altered development 
and impaired Notch1 signaling. However, the authors ac-
knowledged that many differences exist between Notch1- 
and  ADAM10-deficient  thymocytes  (Wolfer  et  al.,  2002; 
Tian  et  al.,  2008),  and  concluded  that  ADAM17  plays  a   
compensatory role in Notch1 cleavage (Tian et al., 2008). 
These reports indicate that ADAM family members perform 
overlapping or compensatory functions.
Four  Notch  receptors,  Notch1–4,  are  expressed  in   
humans and rodents (Kopan and Ilagan, 2009). However, 
previous studies have only addressed Notch1 activation. It is 
unclear whether conclusions drawn from studies on Notch1 
cleavage can be generalized to other Notch receptors. Spe-
cifically, the Notch1 cleavage site recognized by ADAMs is 
not present in mouse Notch2 (Brou et al., 2000). Addition-
ally, the phenotype of ADAM10/ embryos was strikingly 
similar  to  that  of  Notch1,4  double  knockout  embryos   
(Hartmann et al., 2002) but quite distinct from features of   
nonviable Notch2 embryos (Hamada et al., 1999). To date, the 
role of ADAMs in Notch2 cleavage has not been examined.
Notch2 signaling regulates B cell development (Tanigaki 
and Honjo, 2007). In contrast to T cells, naive B cells prefer-
entially express Notch2, and express extremely low levels of 
Notch1,  Notch3,  and  Notch4  (Saito  et  al.,  2003;  Santos   
et al., 2007; Moriyama et al., 2008). As immature B cells enter 
the spleen as transitional cells, they either differentiate into   
follicular (FO) B cells or cells of the marginal zone B cell   
(MZB) lineage. Notch2 signaling is required for develop-
ment of the MZB lineage (Saito et al., 2003), which initiates 
critical immune responses to bloodborne infections and per-
forms important roles in antigen transport and presentation 
(Pillai et al., 2005). During MZB development, the Notch2 
heterodimer binds ligands such as Dll1 present on stromal and 
antigen-presenting cells (Hozumi et al., 2004). Binding initi-
ates proteolytic processing of the receptor by an unidentified 
metalloproteinase, which leads to the release of the Notch JEM VOL. 207, March 15, 2010 
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ADAM10 is indispensable for MZB development
Because  reductions  in  ADAM10  activity  modestly  impair   
thymocyte development (Manilay et al., 2005; Tian et al., 
2008), we examined the role of ADAM10 in B cell develop-
ment. Early development was not altered in ADAM10∆/∆cre+/ 
mice. The percentage of pro– and pre–B cells (B220+IgM) 
and immature B cells (B220+IgM+) in the bone marrow did 
not differ between ADAM10∆/∆ and ADAM10∆/∆cre+/ mice 
(Fig. S3 A). Additionally, deletion of ADAM10 did not alter 
the level of B1 cells in the peritoneum (Fig. S4). In contrast, 
further B cell development in the spleen was drastically altered. 
Most interestingly, MZBs (CD23low/CD21/35hiIgMhi) were 
not present in ADAM10∆/∆cre+/EYFP+ mice (Fig. 2, B 
and D). Immunohistochemical staining of spleen cryosections   
revealed a complete absence of IgMhi-expressing MZBs   
surrounding the marginal sinus, labeled with the metallophilic 
macrophage marker 1 (MOMA-1; Fig. 2 E). Additionally,   
development  of  precursors  to  MZBs,  (CD23int/hiCD21/
35hiIgMhi; Fig. 2, A and D), was severely abrogated. Thus, 
there was also a dramatic decrease in CD1dhiCD9hi B cells, 
which include PMZB and MZB populations (Fig. 2 C).
The development of transitional B cells was moderately 
altered  by  ADAM10  deletion.  The  level  of  T2  B  cells 
(CD23+CD21/35intAA4.1+)  was  significantly  decreased  in 
knockout mice (Fig. 2 D and Fig. S5), whereas the percent-
age of T1 cells (CD23low/CD21/35lowIgMhi) was modestly 
elevated compared with heterozygotes (Fig. 2, B and D).   
by crossing mice containing loxP sites surrounding exon 
9  of  ADAM10  (ADAM10∆/∆)  with  CD19cre  knockin   
animals (Fig. S1; Rickert et al., 1997). PCR analysis of 
DNA isolated from B220+ and B220 splenocytes indicated 
that cre-mediated recombination of exon 9 occurs in an   
efficient B cell–specific manner in ADAM10∆/∆CD19cre+/ 
(ADAM10∆/∆cre+/) mice (Fig. 1 A). To better assess the 
sensitivity and cell specificity of recombination, we gener-
ated ADAM10∆/∆CD19cre+/R26R-EYFP+ (ADAM10∆/∆ 
cre+/EYFP+) mice that express the EYFP transgene after 
cre-mediated recombination (Srinivas et al., 2001). Dele-
tion of exon 9, which encodes the Zn-binding domain of 
the protease active site, produces a frameshift mutation that 
interrupts transcription. Thus, recombination of ADAM10 
in  ADAM10∆/∆cre+/EYFP+  mice  resulted  in  the  loss   
of  ADAM10  mRNA  and  protein  expression  in  EYFP+ 
cells, including FO and T1 spleen B cells (Fig. 1, B and C). 
Because ADAM10 surface expression is only detectable on 
EYFP cells (unpublished data), EYFP is a reliable reporter 
for ADAM10 deletion. Recombination detected by EYFP 
expression occurs in 87 and 95% of B220+ B cells in the 
spleen and peripheral LNs (PLNs), respectively (Fig. S2 A). 
In addition, 96 and 98% of EYFP+ cells from the spleen 
and  PLNs  express  B220.  This  data  combined  with  the   
lack of EYFP expression by B220 cells and Thy1+ (CD90) 
T cells indicates that recombination occurs exclusively in   
B lymphocytes (Fig. S2 B).
Figure 1.  ADAM10∆/∆CD19cre+/ mice are B cell–specific ADAM10 knockouts. (A) PCR products for exon 9 of ADAM10 performed on isolated 
DNA, using primers P1 and P2 (Fig. S1). Spleen B220+ B cells and B220 non–B cells from the indicated mice were sorted via FACS. 955- and 217-bp 
bands represent full-length and recombined ADAM10, respectively. (B) RT-PCR for ADAM10 mRNA isolated from FO and T1 spleen B cells. FO B cells iden-
tified as B220+CD23int/hiCD21/35intIgMint and T1 B cells identified as B220+CD23low/CD21/35lowIgMhi were isolated via FACS. (C) Flow cytometric analysis  
of ADAM10 expression on the surface of FO and T1 spleen B cells from the indicated mice. Sorted and analyzed cells from EYFP+ mice were identified as 
EYFP+ instead of B220+. Data are representative of three independent experiments.626 ADAM10 activates Notch2 and MZB development | Gibb et al.
Figure 2.  ADAM10 is essential for MZB lineage development. (A and B) Flow cytometric analysis of spleen B cells labeled for CD21/35 and IgM 
expression, gated on (A) B220+CD23int/hi and (B) B220+CD23low/ cells. (C) Analysis of PMZBs and MZBs labeled for CD1d and CD9 expression. Flow  
cytometric plots in A–C are representative of six experiments. (D) Levels of B cell subsets are expressed as the percentage of total spleen B cells (n = 6 
except for T2 cells [n = 3]). Data are cumulative from six independent experiments for all subsets except for T2 cells, which are cumulative from three JEM VOL. 207, March 15, 2010 
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from ADAM10∆/∆ and ADAM10∆/+cre+/ mice (Fig. 3 E), and 
increased sCD23 levels in culture supernatants (Fig. 3 F). In 
contrast, 19G5 did not influence the level of mCD23 on 
purified ADAM10-null B cells and did not enhance re-
lease of sCD23 into supernatants. This result further demon-
strates that cleavage of CD23 from ADAM10-null B cells is 
severely impaired.
CD23 expression does not regulate MZB development
Deletion of ADAM10 had profound effects on CD23 cleavage 
and MZB lineage development. Thus, we examined the role 
of CD23 in MZB development. Levels of MZBs in wild-type 
C57BL/6, CD23 transgenic (Payet et al., 1999), CD23/ (Yu 
et al., 1994), and ADAM10∆/∆cre+/EYFP+ mice were deter-
mined by labeling IgM, IgD, and CD21/35 on splenocytes. 
IgMhiIgDlow spleen B cells are a heterogeneous population in-
cluding T1 cells and MZBs. However, T1 cells and MZBs are 
CD21/35low  and  CD21/35hi,  respectively.  Flow  cytometric 
analysis demonstrated that the percentage of IgMhiIgDlowCD21/
35hi MZBs in CD23 transgenic and CD23/ spleens did not 
differ from C57BL/6 mice. In contrast, similarly defined cells 
were not present in ADAM10∆/∆cre+/EYFP+ spleens (Fig. 4). 
Thus, ADAM10 mediates MZB development by a mechanism 
independent of CD23 cleavage.
ADAM10 initiates Notch2 signaling
Previous  studies  demonstrated  that  ADAM10-deficient 
mouse embryos resemble Notch1,4-deficient embryos (Swiatek 
et al., 1994; Hartmann et al., 2002), and Notch1 signaling   
is altered in ADAM10-null thymocytes (Tian et al., 2008). 
Although Notch1, Notch3, and Notch4 are minimally ex-
pressed by naive mouse B cells, signaling through the Notch2 
receptor is critical for MZB development (Saito et al., 2003; 
Santos et al., 2007; Moriyama et al., 2008). Thus, we consid-
ered the possibility that ADAM10 is required for Notch2 
signaling. Interestingly, ADAM10 and Notch2 are both pref-
erentially expressed on cells of the MZB lineage, including 
PMZBs and MZBs (Fig. S7, A and B). ADAM-mediated 
cleavage of Notch receptors initiates the release of the NICD 
that mediates downstream signaling. However, rapid degra-
dation prevents detection of physiological levels of NICD 
(Kopan and Ilagan, 2009). Thus, to determine if ADAM10 is 
required for Notch2 signaling in B cells, we examined the 
expression  of  Notch2  target  genes,  including  CD21/35, 
Hes1, Hes5, and Dtx1.
Multiple reports have demonstrated that Notch signaling 
enhances expression of CD21/35 (Strobl et al., 2000; Makar   
et al., 2001). By generating Notch2fl/CD19cre+/ mice, Saito 
et al. (2003) demonstrated that Notch2 signaling may regulate 
CD21/35 expression in B cells. Deletion of Notch2 resulted 
Finally, although the percentage of total B cells in the spleen 
was not altered (Fig. S3 B), levels of FO B cells (CD23int/
hiCD21/35intIgMint) were significantly elevated in ADAM10∆/∆ 
cre+/EYFP+ mice compared with controls (Fig. 2, A and D).   
The increase in FO B cells and the reduction in PMZBs in-
dicate a developmental defect rather than impaired mainte-
nance of the MZB population. Thus, ADAM10 is essential 
for development of the entire MZB lineage.
ADAM10 is the primary sheddase of CD23 in vivo
Precursors  of  MZBs  down-regulate  surface  expression  of 
CD23 as they differentiate (Pillai et al., 2005). Given that   
in vitro studies have demonstrated the ability of ADAM10 to 
cleave CD23 (Weskamp et al., 2006; Lemieux et al., 2007), we 
considered that ADAM10 may be required for in vivo CD23 
cleavage, which may regulate MZB development. To deter-
mine whether ADAM10 cleaves CD23 in vivo, we examined 
the levels of membrane-bound CD23 (mCD23) on B cells and 
soluble CD23 (sCD23) in the serum of ADAM10∆/∆cre+/ and 
control  mice.  Flow  cytometric  and  immunohistochemical 
analyses revealed that deletion of ADAM10 resulted in a dra-
matic increase in mCD23 (Fig. 3 and Fig. S6). mCD23 was 
significantly elevated on FO B cells, total spleen B cells, and 
PLN B cells (Fig. 3, A and B; and Fig. S6, A and B). Immuno-
histochemical labeling illustrates this profound increase on B 
cells within the spleen follicle, surrounded by the marginal   
sinus, labeled with MOMA-1 (Fig. 3 C). Deletion of ADAM10 
from B cells also significantly reduced the amount of sCD23 
detected in the serum of ADAM10∆/∆cre+/ mice by 69.1% 
compared with ADAM10∆/∆ controls (Fig. 3 D). Importantly, 
deletion  of  ADAM10  did  not  alter  CD23  mRNA  levels   
(Fig. S6 C). Thus, ADAM10 clearly regulates CD23 surface ex-
pression through posttranslational proteolysis. These data indi-
cate that ADAM10 is the primary sheddase of CD23 in vivo.
Although this result demonstrates that other proteases do 
not compensate for the absence of ADAM10, a low level of 
sCD23 was measured in the serum of ADAM10∆/∆cre+/ mice. 
This may have been the result of incomplete cre-mediated   
recombination in B cells (Fig. S2 A), trans-cleavage of CD23 
by secreted proteases or ADAM10-expressing non–B cells, or 
cleavage of mCD23 from FDCs. To evaluate cleavage in the 
complete absence of ADAM10, we purified EYFP+ FO B cells 
from spleens of ADAM10∆/∆cre+/EYFP+ mice. These iso-
lated cells and FO B cells from control mice were stimulated 
with CD40L and IL-4 to promote mCD23 expression before 
the addition of the anti-CD23 stalk antibody, 19G5, or an iso-
type control antibody, C0H2. Antibody binding to the coiled-
coil stalk region of CD23 disrupts the homotrimeric structure of 
mCD23 and promotes mCD23 cleavage (Ford et al., 2006). As 
expected, 19G5 reduced mCD23 levels on FO B cells isolated 
independent experiments. In A–D, FO and T1 cells were identified as in Fig. 1. MZBs, T2 cells, and PMZBs were identified as follows: T2 cells, B220+CD23+CD21/
35intAA4.1+; MZBs, B220+CD23low/CD21hiIgMhi; and PMZBs, B220+CD23int/hiCD21/35hiIgMhi. Numbers on plots indicate the percentage of B220+ cells in 
boxes. Cells from ADAM10∆/∆cre+/EYFP+ mice were identified as EYFP+ instead of B220+. Error bars represent the SEM between samples. (E) Immunohisto-
chemical labeling of spleen follicles for MOMA-1, IgM, and IgD expression. Data are representative of three independent experiments. Bar, 100 µm.
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A and B) and PLN B cells, respectively (Fig. S8). Immunohisto-
chemical staining of spleen follicles verified that the reduced 
expression was specific to B cells. Although CD21/35 labeling 
of ADAM10∆/∆cre+/ follicles was generally diminished, we   
observed concentrated areas of intense staining (Fig. 5 E). 
in a significant decrease in CD21/35 surface expression. Our 
analysis of ADAM10∆/∆cre+/ B cells revealed that ADAM10 
regulates CD21/35 expression in a remarkably similar manner. 
Deletion of ADAM10 resulted in a 61 and 67% reduction in 
CD21/35 expression on the surface of spleen FO B cells (Fig. 5, 
Figure 3.  ADAM10 is the primary in vivo sheddase of CD23. (A) Cell-surface expression of CD23 on spleen FO B cells from the indicated mice. Data 
are representative of six independent experiments. (B) Mean fluorescent intensity (MFI) of mCD23 expression by FO B cells (B220+CD21intIgMint; n = 6).  
(C) Immunohistochemical staining of spleen cryosections from the indicated mice. CD23-PE and MOMA-1–FITC labeling of metallophilic macrophages in 
the marginal sinus surrounding spleen follicles is shown. Data are representative of three independent experiments. Bar, 100 µm. (D) Serum sCD23 levels 
measured by ELISA (n = 4). (E and F) Cleavage of CD23 on FO B cells treated with 19G5 or C0H2 ex vivo. FO B cells isolated from spleens as in Fig. 1 B were 
cultured for 24 h with CD40L, IL-4, and 8:A3 to elevate mCD23 levels before washing and culture with 100 µg 19G5 or C0H2 with fresh cytokines. Cells 
and supernatants were collected 17 h later and analyzed for mCD23 expression via flow cytometry (E) and sCD23 via ELISA (F), respectively (n = 4). Data  
in D–F are representative and cumulative from four independent experiments. Error bars represent the SEM between samples.JEM VOL. 207, March 15, 2010 
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ulated by Notch2 signaling (Saito et al., 2003). Thus, ADAM10 
regulates signaling through the Notch2 receptor.
We considered the possibility that ADAM10 may be   
required for the expression of critical Notch2 signaling com-
ponents, including the Notch2 receptor or the transcription 
factor RBP-J. However, Notch2 and RBP-J expression 
were not altered in ADAM10-null B cells (Fig. S7 C and not 
depicted). In addition, engagement of the Notch2 ligand, 
Dll1, expressed on spleen stromal cells, antigen-presenting 
cells,  and  FDCs  (Yoon  et  al.,  2009)  is  also  required  for 
Notch2 signal activation and MZB development (Hozumi   
et al., 2004). Impaired interaction between ADAM10-null   
B  cells  and  Dll1-expressing  cells  in  the  spleen  could  also   
result in decreased expression of Notch2 targets in primary   
B cells. To directly determine whether ADAM10-null B cells 
are capable of responding to Dll1, purified FO B cells were 
stimulated in the presence of an Fc-Dll1 chimera or control 
mouse IgG. Fc-Dll1 stimulated expression of Dtx1, Hes1, 
and Hes5 in control B cells cultured for 36, 60, or 84 h. Peak 
expression was observed at 60 h. In contrast, ADAM10-null 
B cells clearly failed to respond to Fc-Dll1 stimulation at any 
time point (Fig. 6 D and not depicted). Thus, B cells lacking 
ADAM10  are  unable  to  respond  to  the  primary  Notch2   
ligand that induces MZB development. Collectively, these 
data confirm that ADAM10 is required for initiating Notch2 
signaling in B cells.
DISCUSSION
In this study, we formally tested the hypothesis that ADAM10 
regulates B cell development. The generation and analysis   
of B cell–specific ADAM10 knockout mice revealed that 
Labeling of these areas with anti-IgG to identify immune 
complexes on FDCs revealed that CD21/35 expression on 
FDCs  was  intact  in  ADAM10∆/∆cre+/  mice  (Fig.  5  F).   
Additionally, the levels of soluble CD21/35 in serum were 
also significantly lower than controls (Fig. 5 C), demonstrat-
ing that all forms of B cell CD21/35 were reduced. Reduc-
tions  in  CD21/35  mRNA  levels  in  sorted  spleen  B  cells 
established that the suppressed protein expression was the   
result  of  diminished  transcriptional  activation  or  mRNA   
stability in ADAM10∆/∆cre+/ B cells (Fig. 5 D).
The absence of MZB development and the diminished ex-
pression of complement receptors in ADAM10∆/∆cre+/EYFP+ 
mice  indicate  that  ADAM10  may  be  required  for  Notch2   
signaling. To further investigate this hypothesis, we measured 
the expression of the canonical Notch targets Dtx1, Hes1, and 
Hes5 in sorted spleen B cells. Real-time PCR analysis revealed 
that expression levels of the Notch2-selective target, Dtx1, and 
the general Notch receptor targets, Hes1 and Hes5, were all 
significantly reduced in EYFP+ spleen FO B cells from 
ADAM10∆/∆cre+/EYFP+ mice compared with ADAM10∆/∆ 
and ADAM10∆/+cre+/ controls (Fig. 6, A–C). Additionally, 
Dtx1 and Hes1 expression in T1 B cells was significantly sup-
pressed in the absence of ADAM10. Expression levels of Notch 
targets in B cells from ADAM10∆/+cre+/ heterozygous mice 
formed a consistent trend of lower expression compared with 
ADAM10∆/∆ mice. ADAM10∆/+cre+/ T1 cells and MZBs ex-
pressed significantly less Hes1 and Dtx1, respectively. These 
results clearly demonstrate that deletion of ADAM10 pro-
foundly impairs Notch signaling in B cells. Although signaling 
through  multiple  Notch  receptors  can  induce  expression  of 
Hes1 and Hes5, expression of Dtx1 and CD21/35 is tightly reg-
Figure 4.  CD23 expression does not regulate MZB development. Flow cytometric analysis of spleen B cells from C57BL/6, CD23/, CD23 trans-
genic (TG), and ADAM10∆/∆cre+/EYFP+ mice labeled for surface expression of IgM, IgD, and CD21/35. (A) Numbers indicate the percentage of B220+ or  
EYFP+ cells in boxes. (B) CD21/35 expression of IgMhiIgDlow B cells boxed in A. Numbers indicate the percentage of B220+IgMhiIgDlow cells within gates  
(T1, B220+IgMhiIgDlowCD21/35low; MZB, B220+IgMhiIgDlowCD21/35hi). Cells from ADAM10∆/∆cre+/EYFP+ mice were identified as EYFP+ instead of B220+.  
Data are representative of three independent experiments.630 ADAM10 activates Notch2 and MZB development | Gibb et al.
Mumm et al., 2000; Bozkulak and Weinmaster, 2009; van 
Tetering et al., 2009). Thus, in vivo inactivation of only 
ADAM10 or ADAM17 may result in a milder phenotype 
than Notch1 inactivation. For example, thymocyte develop-
ment was altered to a lesser degree in ADAM10-deficient 
thymocytes  compared  with  Notch1-deficient  thymocytes 
generated with the same cre-expressing transgene (Wolfer   
et al., 2002; Tian et al., 2008).
In contrast, the phenotype of B cell–specific ADAM10 
knockout mice described in this study is strikingly similar   
to the phenotype reported for Notch2 B cell knockouts.   
Although the thymocyte-specific knockout mice were gen-
erated with a different ADAM10 loxP/loxP allele, the stronger 
B cell phenotype may indicate that ADAM10 is the only pro-
tease that recognizes the Notch2 cleavage site, which is distinct 
from the Notch1 site previously described (Brou et al., 2000). 
ADAM10 critically regulates development of the entire   
MZB lineage by initiating Notch2 signaling.
The rate-limiting step in Notch2 signaling is cleavage within 
the receptor’s negative regulatory region (NRR) located in the 
membrane-proximal portion of the extracellular domain. The 
structure  of  the  NRR  prevents  ligand-independent  Notch 
cleavage. Mutations in the NRR can allow cleavage in the 
absence of ligand, leading to constitutive Notch signaling. In 
the case of Notch1, this leads to the formation of T cell acute 
lymphocytic leukemia (Kopan and Ilagan, 2009). Brou et al. 
(2000) and Mumm et al. (2000) identified the Notch1 cleav-
age site in the NRR between Ala-1710 and Val-1711, just 
13  amino  acids  upstream  of  the  transmembrane  domain. 
These  studies,  in  combination  with  more  recent  reports, 
have demonstrated that ADAM10, ADAM17, and possibly 
other proteases recognize this cleavage site (Brou et al., 2000; 
Figure 5.  CD21/35 expression is reduced in ADAM10∆/∆CD19cre+/ mice. (A) Cell-surface expression of CD21/35 on spleen FO B cells. Data are 
representative of four independent experiments. (B) Quantified mean fluorescence intensity (MFI) from A. (C) Serum-soluble CD21/35 measured by ELISA 
(n = 5; data are cumulative from five independent experiments). (D) Quantitative PCR of CD21/35 mRNA expression in B220+ spleen cells relative to 18S 
expression (n = 4; data are cumulative from four independent experiments). Error bars represent the SEM between samples. (E) Immunohistochemistry  
of spleen follicles labeled with IgM-AMCA and CD21/35-PE. Arrows indicate MZBs with overlay staining. Bars, 100 µm. (F) Higher magnification of intense 
CD21/35 labeling in the ADAM10∆/∆cre+/ follicles shown in E. FDC immune complexes (ICs) are labeled with anti-IgG–AMCA. Bar, 50 µm. Immunohisto-
chemistry is representative of three independent experiments.JEM VOL. 207, March 15, 2010 
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a lack of understanding of signal activation. Certainly, identi-
fying the proteinase responsible for initiating the irreversible 
signaling cascade represents significant progress for attempts 
to control Notch2-related diseases, including B-CLL.
Our finding that ADAM10 is the principal sheddase of 
CD23 in vivo resolves earlier data describing CD23 cleavage 
by multiple ADAMs in vitro (Fourie et al., 2003; Weskamp   
et al., 2006). Demonstration that CD23 cleavage is sensitive 
to hydroxamic acid inhibitors, which inhibit the proteolytic 
activity of ADAMs, stimulated significant progress toward 
identifying the sheddase (Conrad et al., 2007). Various stud-
ies have ruled out a role for ADAMs 8, 9, 12, 15, and 17 in 
vivo (Weskamp et al., 2006; Le Gall et al., 2009). A recent 
study determined that MMP-9 cleaves CD23 in LPS-treated 
mice (Jackson et al., 2009). However, MMP-9–dependent 
cleavage was not examined in naive mice, and a role for 
ADAM10 was not excluded. In this study, we demonstrate 
that deletion of ADAM10 from B cells profoundly impairs 
CD23 cleavage in vivo, resulting in a dramatic increase in the 
level of CD23 expressed on the B cell surface, and a pro-
found reduction in sCD23.
This finding has important implications for the treatment 
of allergic and inflammatory reactions. Binding of IgE to 
CD23 on the B cell surface promotes transport and presenta-
tion of antigen associated with IgE immune complexes 
(Hjelm et al., 2008). In addition, mCD23 has been proposed 
as a natural repressor of IgE synthesis (Conrad et al., 2007). 
However, cleavage of CD23 from the cell surface may interrupt 
The effects of ADAM10 deletion on MZB development, 
CD21/35 expression, Dtx1 expression, and Dll1-stimulated 
Notch  signaling  clearly  demonstrate  ADAM10’s  role  in 
Notch2 signaling. However, we do not rule out the possibil-
ity that ADAM10 may also be required for signaling through 
other minimally expressed Notch receptors on B cells. In 
fact, quantification of Hes1 and Hes5 expression revealed a 
more significant impairment of Notch signaling in ADAM10-
null B cells than reported for Notch2-null B cells (Saito et al., 
2003). This may reflect a greater purity of EYFP+ ADAM10-
null B cells, or the ability of other minimally expressed Notch 
receptors to signal in the absence of Notch2 but not in the 
absence of ADAM10. Nevertheless, the effect on MZB devel-
opment is clearly caused by impaired Notch2 signaling, and 
contrary to studies in thymocytes, this study describes an abso-
lute requirement for ADAM10 activity in the development 
of a lymphocyte subset.
Our finding that ADAM10 initiates Notch2 signaling has 
important implications for the treatment of Notch-related 
diseases. Disregulated Notch signaling underlies numerous 
human pathologies ranging from developmental impairments 
to cancer (Kopan and Ilagan, 2009). Specifically, unregulated 
Notch2 signaling is a defining characteristic of B cell chronic 
lymphocytic  leukemia  (B-CLL),  diffuse  large  B  cell  lym-
phoma, and marginal zone lymphoma (Troen et al., 2008; Lee 
et al., 2009; Rosati et al., 2009). Although many regulators 
of Notch2 signaling have been described, progress in using 
these findings for therapeutic purposes has been restricted by 
Figure 6.  ADAM10 initiates Notch2 signaling. (A–C) Gene expression of targets of Notch2 signaling in primary B cells determined by quantitative 
real-time PCR. Data are cumulative from at least four independent experiments. T1 cells, FO cells, PMZBs, and MZBs identified as in Fig. 2 were sorted via 
FACS (A, n = 7; B, n = 4; and C, n = 4) Expression by PMZBs and MZBs from ADAM10∆/∆cre+/EYFP+ mice was not determined because of cell loss (Fig. 2). 
(D) Expression of Dtx1 in FO B cells stimulated with CD40L and Fc-Dll1 or control mouse IgG for 60 h, with expression relative to 18S expression (n = 3; 
data are cumulative from three independent experiments). Error bars represent the SEM between samples. n.d., not determined.632 ADAM10 activates Notch2 and MZB development | Gibb et al.
B cells. ADAM10-null B cells also express elevated CD23 
and reduced CD21/35, which also regulate antibody pro-
duction (Croix et al., 1996; Payet et al., 1999). Thus, the role 
of ADAM10 in adaptive immune responses may be extensive 
and warrants further study.
In conclusion, examination of CD23 and Notch2 cleavage 
in B cell–specific ADAM10 knockout mice has shown that 
other proteases do not compensate for a lack of ADAM10 
activity in vivo. This study demonstrates that ADAM10 is the 
primary sheddase of CD23 in vivo. Moreover, it reveals that 
ADAM10 critically regulates MZB lineage development by 
initiating Notch2 signaling.
MATERIALS AND METHODS
Mice. Generation of ADAM10flox/flox mice on the C57BL/6J (B6) back-
ground was performed by inGenious Targeting Laboratories and is illustrated 
in Fig. S1. In brief, a targeting vector containing intron 8, exon 9, and intron 
9  of  mouse  Adam10  was  inserted  in  the  Adam10  gene  via  homologous   
recombination. The inserted sequence contains a neomycin (Neo) cassette 
flanked by FRT and loxP sites for selection of embryonic stem cell clones. 
Once ADAM10flox/+ founders with germline transmission were established, 
the Neo cassette was removed from the germline by mating progeny with 
ACT-FLPe+/+ transgenic mice expressing the FLP recombinase under con-
trol of the human ACTB promoter. This generated ADAM10∆/+ mice con-
taining exon 9 flanked by loxP sites in introns 8 and 9. Crossing ADAM10∆/∆ 
and CD19cre+/+ knockin mice generated ADAM10∆/+CD19cre+/ hetero-
zygotes. ADAM10∆/∆CD19cre+/ mice were generated by crossing hetero-
zygotes  with  ADAM10∆/∆  mice.  R26R-EYFP+  mice  crossed  with 
ADAM10∆/∆CD19cre+/  mice  produced  ADAM10∆/∆CD19cre+/R26R-
EYFP+ mice. CD19cre+/+ knockin and R26R-EYFP+ transgenic mice on a 
C57BL/6 background were obtained from the Jackson Laboratory. CD23 
transgenic and CD23/ mice were previously described (Yu et al., 1994; 
Payet et al., 1999). C57BL/6 mice were wild-type littermates of CD23 trans-
genics. All mouse protocols were approved by the Virginia Commonwealth 
University Animal Care and Use Committee.
Flow cytometry and cell sorting. Single-cell suspensions of PLN cells 
and splenocytes were created by disrupting inguinal, brachial, and axillary 
LNs and spleens between glass slides. After red blood cell lysis, filtered cells 
were labeled with antibodies including B220-FITC (RA3-6B2), Thy1.2-PE 
(30-H12),  IgD-PE  (11-26c.2a),  CD9-PE  (MZ3),  CD11b-PE  (M1/70), 
IgM-allophycocyanin (APC; RMM-1), CD1d-PerCP/Cy5.5 (1B1), CD23-
PE/Cy7 (B3B4), and biotinylated CD21/35 (7E9) from BioLegend; CD3-
PE (2C11) and CD21/35-PE (7G6) from BD; CD5-APC (53-7.3) and 
AA4.1-APC from eBioscience; and ADAM10-PE (FAB946) from R&D 
Systems, used at 0.25 µg/106 cells, and biotinylated HMN2-35 (Moriyama 
et al., 2008), used at 0.5 µg/106 cells for 30 min on ice. Cells labeled with 
biotinylated antibodies were washed twice and stained with streptavidin–
  energy-coupled dye (Beckman Coulter) for 30 min. Flow cytometric analy-
sis was performed using an FC500 (Beckman Coulter), or a FACSCanto or 
FACSAria II (BD). Overlays of histograms were generated in SigmaPlot 
10.0 software as line plots and smoothed using the SMOOTH transform. 
For FACS, T cells were depleted with CD90.2-conjugated magnetic beads 
(MACS; Miltenyi Biotec). The remaining B220+ or EYFP+ B cell subsets 
were  sorted  with  a  FACSAria  II  according  to  the  following  criteria:   
FO cells, CD23int/hiCD21intIgMint; PMZBs, CD23int/hiCD21hiIgMhi; T1 
cells,  CD23low/CD21lowIgMhi;  and  MZBs,  CD23low/CD21hiIgMhi.   
Experiments were only conducted with cell purity levels >95%.
PCR,  RT-PCR,  and  quantitative  PCR. Total RNA was extracted   
and purified from sorted B cells from mouse spleens using TRIzol reagent 
(Invitrogen). Samples were treated with DNase (Takara Bio Inc.), mixed 
with phenol/chloroform/isoamyl alcohol solution (25:24:1; USB), and   
this  negative  feedback  mechanism  and  result  in  elevated   
IgE synthesis. Additionally, the cleaved product, sCD23, is 
elevated in synovial fluids of patients with rheumatoid arthri-
tis and may contribute to disease by activating monocytes 
(Lecoanet-Henchoz et al., 1995; Ribbens et al., 2000). Thus, 
inhibiting cleavage by the endogenous CD23 sheddase has 
been  proposed  as  a  novel  therapy  for  controlling  allergic   
and rheumatic disease (Conrad et al., 2007). Moreover, an 
increased sCD23 level in the serum of patients with B-CLL 
is a negative prognostic indicator for survival (Sarfati et al., 
1996). Given that constitutive Notch2 signaling and CD23 
cleavage in B-CLL cells are well established (Sarfati et al., 
1996; Rosati et al., 2009), this study indicates that ADAM10 
is a potential target for B-CLL therapy.
Given the structural similarity of many ADAMs and the 
highly conserved nature of sequences within proteinase   
domains, we were surprised to find that deletion of ADAM10 
had such profound effects on CD23 cleavage and Notch2 
signaling. ADAM10 shares the greatest sequence similarity 
with ADAM17 (Black and White, 1998). Previous studies 
using ADAM10/ MEFs have indicated considerable over-
lap in substrate recognition between multiple ADAMs, and 
especially between ADAMs 10 and 17 (Hinkle et al., 2004; 
Sahin et al., 2004; Le Gall et al., 2009). Although B cells   
also express ADAM17 (Contin et al., 2003), we found no 
evidence of significant compensatory mechanisms while   
examining primary ADAM10-null B cells or cells stimulated 
to enhance CD23 cleavage or Notch2 signaling. Although 
we did not examine ADAM17-null B cells, Li et al. (2007)  
demonstrated that reconstitution of RAG1/ mice with 
bone  marrow  cells  lacking  the  Zn-binding  domain  of 
ADAM17 resulted in unaltered B cell development. Addi-
tionally,  CD23  cleavage  is  not  altered  in  B  cell–specific 
ADAM17 knockout mice (Le Gall et al., 2009). Thus, this 
study reveals that substrate recognition by specific ADAMs 
may be more stringent in vivo than in vitro studies would 
predict. This indicates that development of specific ADAM 
inhibitors may be more efficacious than previously thought.
The requirement for ADAM10 in Notch2 signaling and 
CD23 cleavage has generated numerous questions about the 
role  of  ADAM10  in  immune  responses.  MZBs  respond 
quickly to T-independent antigens by secreting IgM, facili-
tate the deposition of immune complexes on FDCs by shut-
tling between the marginal zone and the spleen follicle, and 
perform a protective role in models of sepsis (Pillai et al., 
2005; Cinamon et al., 2008). Thus, it is likely that these   
responses are impaired in ADAM10∆/∆cre+/ mice. Notwith-
standing  MZBs,  Thomas  et  al.  (2007)  demonstrated  that 
Notch  signaling  promotes  B  cell  activation  by  enhancing   
B cell receptor and CD40 signaling. Synergy also exists be-
tween Notch and NF-B signaling, which influences multiple 
B cell functions (Moran et al., 2007). Additionally, Santos et al. 
(2007) demonstrated that Notch1 activity, which is induced 
in LPS-stimulated B cells, promotes the differentiation of   
antibody-secreting  B  cells.  This  has  stimulated  interest  in 
ADAM10’s role in regulating Notch1 signaling in activated JEM VOL. 207, March 15, 2010 
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examined  with  a  confocal  laser  scanning  microscope  (TCS-SP2  AOBS; 
Leica) fitted with an oil Plan-Apochromat 40× objective. Three lasers were 
used: blue diode (405 nm) for AMCA, argon (488 nm) for FITC, and HeNe 
(543 nm) for PE. Parameters were adjusted to scan at a 512 × 512 pixel   
density and an 8-bit pixel depth. Emissions were recorded in three separate 
channels. Digital images were captured, overlaid, and processed with the 
Confocal and LCS Lite programs (Leica).
Statistical  analysis. p-values were calculated using unpaired two-tailed 
Student’s t tests. Error bars represent the SEM between samples.
Online supplemental material. Fig. S1 is a schematic of the ADAM10∆ 
allele.  Fig.  S2  shows  that  CD19cre-mediated  recombination  of  Adam10 
is B cell specific. Fig. S3 demonstrates that the levels of pro–/pre–B cells, 
immature B cells, and total spleen B cells are not altered in ADAM10∆/∆ 
CD19cre+/  mice.  Fig.  S4  shows  that  B1  cell  development  is  not   
affected  by  ADAM10  deletion.  Fig.  S5  shows  the  percentage  of  T2   
B cells in the spleens of ADAM10∆/∆cre+/EYFP+ and control mice. Fig. S6 
shows that membrane CD23 levels are also significantly elevated on total 
spleen and PLN B cells, whereas the level of CD23 mRNA is unaffected. 
Fig. S7 shows that ADAM10 and Notch2 are preferentially expressed on 
PMZBs and MZBs, and ADAM10 deletion does not alter surface expres-
sion of Notch2. Fig. S8 shows that CD21/35 surface expression is also   
significantly decreased on PLN B cells. Table S1 provides primer and probe 
sequences.  Online  supplemental  material  is  available  at  http://www.jem 
.org/cgi/content/full/jem.20091990/DC1.
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